Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise
Xenon Pharmaceuticals (NasdaqGM:XENE) drew investor attention after reporting positive topline Phase 3 results for its lead drug candidate, azetukalner, followed by an upsized public offering that raised nearly US$750 million.
See our latest analysis for Xenon Pharmaceuticals.
At a share price of US$54.48, Xenon has given investors a 22.22% 1 month share price return and a 59.02% 1 year total shareholder return. This suggests momentum has picked up around the Phase 3 readout and capital raise.
If the azetukalner news has you looking across the sector, it could be a good moment to broaden your watchlist with a curated set of 34 healthcare AI stocks.
With strong recent returns and shares trading at a meaningful discount to the average analyst price target, the key question now is whether Xenon is still undervalued or if the market is already pricing in future growth.
Most Popular Narrative: 45.5% Undervalued
With Xenon last closing at $54.48 and the most followed fair value marker sitting at $100, the current price implies a wide gap that this narrative tries to explain.
A broad ion channel pipeline that includes Nav1.7, Kv7 and Nav1.1 programs now in or approaching clinical stages creates multiple potential follow on products in epilepsy and pain, which, over time, can diversify cash flows and reduce reliance on a single asset for future earnings growth.
Curious what kind of revenue ramp, margin shift and valuation multiple are baked into that $100 figure? The narrative leans on bold growth, improving profitability and a premium earnings multiple that is far from typical for this sector.
Result: Fair Value of $100 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, it is worth remembering that setbacks in azetukalner’s Phase 3 programs or slower than expected uptake in crowded epilepsy and depression markets could quickly challenge this bullish story.
Find out about the key risks to this Xenon Pharmaceuticals narrative.
Another Angle: Expensive On Book Value
While the SWS DCF model points to Xenon trading well below an estimated future cash flow value of $311.26, the picture looks very different when you look at the P/B ratio. At 8.9x, Xenon is well above the US biotech average of 2.4x and sits below a peer average of 18.2x. This raises a simple question for you: is this pricing in opportunity or extra risk?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment clearly split between opportunity and risk, it makes sense to look at the numbers yourself and move quickly to build your own view using these 3 key rewards and 3 important warning signs.
Looking for more investment ideas?
Do not stop at one compelling story. Use this momentum to scan a wider field of opportunities and keep your watchlist working harder for you.
- Spot potential mispricings early by checking stocks highlighted in the 61 high quality undervalued stocks.
- Build a steadier income stream by reviewing companies featured in the 12 dividend fortresses.
- Prioritise resilience by focusing on businesses surfaced in the 67 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com